Literature DB >> 34981326

Analysis of the Management of Cholelithiasis in Bariatric Surgery Patients: a Single-Center Experience.

Carlos Gustavo Petrola Chacón1, Ramón Vilallonga2, Óscar González López3, Amador García Ruiz de Gordejuela2, Marc Beisani4, Enric Caubet Busquet2, Jose Manuel Fort2, Manel Armengol Carrasco1.   

Abstract

PURPOSE: Cholelithiasis is an issue in bariatric surgery patients. The incidence of cholelithiasis is increased in morbidly obese patients. After bariatric surgery, the management maybe sometimes challenging. There is no consensus about how to deal with cholelithiasis prior to bariatric surgery.
MATERIALS AND METHODS: A retrospective review from our prospectively collected bariatric surgery database. Primary bariatric procedures from 2009 to 2020 were included. Prevalence of cholelithiasis and its management prior to bariatric surgery and the incidence and management of postoperative biliary events were analyzed.
RESULTS: Over 1445 patients analyzed, preoperatively cholelithiasis was found in 153 (10.58%), and 68 out of them (44.44%) were symptomatic. Seventy-six patients had a concomitant cholecystectomy. In those cases, the bariatric procedure did not show increased operative time, length of stay, morbidity, or mortality compared to the rest of primary bariatric procedures. Twelve patients (15.58%) with previous cholelithiasis and no concomitant cholecystectomy presented any kind of biliary event and required cholecystectomy. De novo cholelithiasis rate requiring cholecystectomy was 3.86%. Postoperative biliary events both in de novo and persistent cholelithiasis population did not show any difference between the type of surgery, weight loss, and other characteristics.
CONCLUSIONS: Cholelithiasis was present in 10.58% of our primary bariatric surgery population. Concomitant cholecystectomy was safe in our series. Non-surgical management of asymptomatic cholelithiasis did not lead to a higher risk of postoperative biliary events. The global postoperative cholecystectomy rate was equivalent to the general population.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Bariatric surgery; Biliary events; Cholelithiasis; Conservative management

Mesh:

Year:  2022        PMID: 34981326     DOI: 10.1007/s11695-021-05883-z

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  45 in total

1.  Elective cholecystectomy during laparoscopic Roux-en-Y gastric bypass: is it worth the wait?

Authors:  Giselle G Hamad; Sayeed Ikramuddin; William F Gourash; Philip R Schauer
Journal:  Obes Surg       Date:  2003-02       Impact factor: 4.129

2.  Cholecystectomy during laparoscopic gastric bypass has no effect on duration of hospital stay.

Authors:  Ahmed R Ahmed; William O'Malley; Joseph Johnson; Thad Boss
Journal:  Obes Surg       Date:  2007-08       Impact factor: 4.129

3.  Prophylactic cholecystectomy, a mandatory step in morbidly obese patients undergoing laparoscopic Roux-en-Y gastric bypass?

Authors:  Mathieu D'Hondt; Gregory Sergeant; Bert Deylgat; Dirk Devriendt; Frank Van Rooy; Franky Vansteenkiste
Journal:  J Gastrointest Surg       Date:  2011-07-13       Impact factor: 3.452

4.  Is routine cholecystectomy justified in severely obese patients undergoing a laparoscopic Roux-en-Y gastric bypass procedure? A comparative cohort study.

Authors:  Ignazio Tarantino; Renè Warschkow; Thomas Steffen; Philipp Bisang; Bernd Schultes; Martin Thurnheer
Journal:  Obes Surg       Date:  2011-12       Impact factor: 4.129

5.  Morbid Obesity Is Associated With Adverse Clinical Outcomes in Acute Pancreatitis: A Propensity-Matched Study.

Authors:  Somashekar G Krishna; Alice Hinton; Veeral Oza; Phil A Hart; Eric Swei; Samer El-Dika; Peter P Stanich; Hisham Hussan; Cheng Zhang; Darwin L Conwell
Journal:  Am J Gastroenterol       Date:  2015-10-20       Impact factor: 10.864

6.  Is concomitant cholecystectomy necessary in obese patients undergoing laparoscopic gastric bypass surgery?

Authors:  O N Tucker; P Fajnwaks; S Szomstein; R J Rosenthal
Journal:  Surg Endosc       Date:  2008-02-21       Impact factor: 4.584

7.  Incidence of postoperative gallstone disease after antiobesity surgery: population-based study from Sweden.

Authors:  Eduard Jonas; Richard Marsk; Finn Rasmussen; Jacob Freedman
Journal:  Surg Obes Relat Dis       Date:  2009-05-04       Impact factor: 4.734

8.  Intraoperative ultrasound and prophylactic ursodiol for gallstone prevention following laparoscopic gastric bypass.

Authors:  D J Scott; L Villegas; T L Sims; E C Hamilton; D A Provost; D B Jones
Journal:  Surg Endosc       Date:  2003-09-10       Impact factor: 4.584

9.  Is routine cholecystectomy required during laparoscopic gastric bypass?

Authors:  Leonardo Villegas; Benjamin Schneider; David Provost; Craig Chang; Daniel Scott; Thomas Sims; Lois Hill; Linda Hynan; Daniel Jones
Journal:  Obes Surg       Date:  2004-01       Impact factor: 4.129

10.  Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013.

Authors:  Marie Ng; Tom Fleming; Margaret Robinson; Blake Thomson; Nicholas Graetz; Christopher Margono; Erin C Mullany; Stan Biryukov; Cristiana Abbafati; Semaw Ferede Abera; Jerry P Abraham; Niveen M E Abu-Rmeileh; Tom Achoki; Fadia S AlBuhairan; Zewdie A Alemu; Rafael Alfonso; Mohammed K Ali; Raghib Ali; Nelson Alvis Guzman; Walid Ammar; Palwasha Anwari; Amitava Banerjee; Simon Barquera; Sanjay Basu; Derrick A Bennett; Zulfiqar Bhutta; Jed Blore; Norberto Cabral; Ismael Campos Nonato; Jung-Chen Chang; Rajiv Chowdhury; Karen J Courville; Michael H Criqui; David K Cundiff; Kaustubh C Dabhadkar; Lalit Dandona; Adrian Davis; Anand Dayama; Samath D Dharmaratne; Eric L Ding; Adnan M Durrani; Alireza Esteghamati; Farshad Farzadfar; Derek F J Fay; Valery L Feigin; Abraham Flaxman; Mohammad H Forouzanfar; Atsushi Goto; Mark A Green; Rajeev Gupta; Nima Hafezi-Nejad; Graeme J Hankey; Heather C Harewood; Rasmus Havmoeller; Simon Hay; Lucia Hernandez; Abdullatif Husseini; Bulat T Idrisov; Nayu Ikeda; Farhad Islami; Eiman Jahangir; Simerjot K Jassal; Sun Ha Jee; Mona Jeffreys; Jost B Jonas; Edmond K Kabagambe; Shams Eldin Ali Hassan Khalifa; Andre Pascal Kengne; Yousef Saleh Khader; Young-Ho Khang; Daniel Kim; Ruth W Kimokoti; Jonas M Kinge; Yoshihiro Kokubo; Soewarta Kosen; Gene Kwan; Taavi Lai; Mall Leinsalu; Yichong Li; Xiaofeng Liang; Shiwei Liu; Giancarlo Logroscino; Paulo A Lotufo; Yuan Lu; Jixiang Ma; Nana Kwaku Mainoo; George A Mensah; Tony R Merriman; Ali H Mokdad; Joanna Moschandreas; Mohsen Naghavi; Aliya Naheed; Devina Nand; K M Venkat Narayan; Erica Leigh Nelson; Marian L Neuhouser; Muhammad Imran Nisar; Takayoshi Ohkubo; Samuel O Oti; Andrea Pedroza; Dorairaj Prabhakaran; Nobhojit Roy; Uchechukwu Sampson; Hyeyoung Seo; Sadaf G Sepanlou; Kenji Shibuya; Rahman Shiri; Ivy Shiue; Gitanjali M Singh; Jasvinder A Singh; Vegard Skirbekk; Nicolas J C Stapelberg; Lela Sturua; Bryan L Sykes; Martin Tobias; Bach X Tran; Leonardo Trasande; Hideaki Toyoshima; Steven van de Vijver; Tommi J Vasankari; J Lennert Veerman; Gustavo Velasquez-Melendez; Vasiliy Victorovich Vlassov; Stein Emil Vollset; Theo Vos; Claire Wang; XiaoRong Wang; Elisabete Weiderpass; Andrea Werdecker; Jonathan L Wright; Y Claire Yang; Hiroshi Yatsuya; Jihyun Yoon; Seok-Jun Yoon; Yong Zhao; Maigeng Zhou; Shankuan Zhu; Alan D Lopez; Christopher J L Murray; Emmanuela Gakidou
Journal:  Lancet       Date:  2014-05-29       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.